scholarly journals Contrast-induced nephropathy in cardiology practice: Risk factors and approaches to prevention

2012 ◽  
Vol 18 (3) ◽  
pp. 222-227
Author(s):  
YU. F. Salakhova ◽  
D. V. Duplyakov ◽  
E. R. Perunova ◽  
S. E. Burnazyan ◽  
E. I. Bazhenova ◽  
...  

Objective. To study the incidence and risk factors of contrast-induced nephropathy (CIN) resulted from percutaneous coronary interventions in cardiology practice. Design and methods. Retrospective analysis of 100 history cases of patients aged 37-73 years (mean age 56,1 ± 6,0 years) was preformed. 0mnipac-350 was used as a contrast agent during angiography. Glomerular filtration rate (GFR) was assessed by Cockroft-Gault formula before and 48 hours after the intervention. The patients were divided into 2 groups depending on the type of intervention: the first group included the patients with planned intervention and the second — with urgent endovascular intervention. Results. In the first group 3,0 % (n = 2) patients developed CIN, and one case was registered (2,95 %) in the second group. It developed in patients with initial decrease of GFR, in patients with diabetes mellitus and with the combination of both factors.

2015 ◽  
Vol 10 (3) ◽  
pp. 158
Author(s):  
Roxana Mehran ◽  
Antonio Colombo ◽  
Pieter Stella ◽  
Rafael Romaguera ◽  
Gennaro Sardella ◽  
...  

Although second-generation drug-eluting stents (DES) have improved outcomes in percutaneous coronary interventions (PCIs), important unmet needs remain. Two symposia at EuroPCR 2015 focused on two challenging scenarios. First, patients with diabetes mellitus (DM) have generally inferior outcomes following PCI. The Cre8™ stent (manufactured by CID Spa, member of Alvimedica Group) has shown unique efficacy in subpopulations of patients with DM during clinical trials. A live case in a patient with diabetes illustrated the challenges of complex multivessel disease. Second, optimising stent selection towards devices that have demonstrated complete and early endothelialisation offers the potential to reduce the duration of dual antiplatelet therapy. The Cre8™ DES features a polymer-free platform and has been associated with low rates of in-stent thrombosis.


2021 ◽  
Vol 15 (8) ◽  
pp. 2515-2518
Author(s):  
Fida Muhammad ◽  
Tahir Mukhtar Sayed ◽  
Muhammad Shahjehan Mirza ◽  
Aisha Bint Raees ◽  
Irfan Majeed ◽  
...  

Objective: To examine the prevalence and associated risk factors of contrast induced nephropathy in patients undergoing multi-vessel percutaneous coronary intervention (PCI). Study Design: Prospective/Observational Place and Duration: The study was conducted at the cardiology department of DHQ Teaching Hospital, Sargodha and Wazirabad Institute of Cardiology, Wazirabad for duration of six months from October 2020 to March 2021. Methods: Total 135 patients of both genders with ages 20 to 80 years undergoing percutaneous coronary intervention were enrolled in this study. Patients’ detailed demographics were recorded after written consent. Contrast induced nephropathy was defined as serum creatinine >0.5mg/dl from baseline value. Risk factors associated with CIN were examined; Data was analyzed by SPSS 23.0. Results: Out of 130 patients 90 (66.7%) were males while 45 (33.3%) were females with mean age 54.87±12.44 years. We found contrast induced nephropathy in 27 (20%) patients. Anemia, diabetes mellitus, hypertension, contrast volume >150ml, congestive heart failure and age >70 years were significantly associated risk factors of contrast induced nephropathy with p-value <0.05. Conclusion: It is concluded that the incidence of contrast induced nephropathy in patients undergoing PCI is high. Significant risk factors for CIN were anemia, age >70 years, diabetes mellitus, contrast volume >150ml and heart failure. Keywords: Percutaneous Coronary Intervention, Contrast Induced Nephropathy, Risk Factors.


2014 ◽  
Vol 17 (1) ◽  
pp. 34-40 ◽  
Author(s):  
Marina Sergeevna Michurova ◽  
Irina Vladimirovna Kononenko ◽  
Olga Mikhailovna Smirnova ◽  
Victor Yur'evich Kalashnikov

Introduction of drug-eluting stents for percutaneous coronary interventions opened novel options for treating coronary heart disease (CHD) in patients with diabetes mellitus. However, mortality and myocardial infarction rates are still higher among diabetes patients. They also require repeated revascularization of the target vessel more often than euglycemic individuals do. Current review discusses possible effects of diabetes compensation by various classes of antihyperglycemic agents on endovascular intervention outcomes.


Sign in / Sign up

Export Citation Format

Share Document